Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2019, Article ID 7498527, 11 pages
https://doi.org/10.1155/2019/7498527
Research Article

Simiao Pill Attenuates Collagen-Induced Arthritis in Rats through Suppressing the ATX-LPA and MAPK Signalling Pathways

Department of Integrated Chinese Traditional and Western Medicine, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, 430070, China

Correspondence should be addressed to Zhe Chen; moc.361@6002ipehz

Received 19 December 2018; Revised 15 February 2019; Accepted 25 February 2019; Published 14 March 2019

Academic Editor: Francesca Mancianti

Copyright © 2019 Pan Shen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. S. Firestein, “Evolving concepts of rheumatoid arthritis,” Nature, vol. 423, no. 6937, pp. 356–361, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. J. S. Smolen, D. Aletaha, and I. B. McInnes, “Rheumatoid arthritis,” The Lancet, vol. 388, no. 10055, pp. 2023–2038, 2016. View at Publisher · View at Google Scholar · View at Scopus
  3. Y. Araki, T. Tsuzuki Wada, Y. Aizaki et al., “Histone methylation and STAT-3 differentially regulate interleukin-6-induced matrix metalloproteinase gene activation in rheumatoid arthritis synovial fibroblasts,” Arthritis Rheumatol, vol. 68, no. 7, pp. 1614–1626, 2016. View at Publisher · View at Google Scholar
  4. I. B. McInnes and G. Schett, “Pathogenetic insights from the treatment of rheumatoid arthritis,” The Lancet, vol. 389, no. 10086, pp. 2328–2337, 2017. View at Publisher · View at Google Scholar · View at Scopus
  5. R. Taniguchi, A. Inoue, M. Sayama et al., “Structural insights into ligand recognition by the lysophosphatidic acid receptor LPA 6,” Nature, vol. 548, no. 7667, pp. 356–360, 2017. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Aoki, A. Inoue, and S. Okudaira, “Two pathways for lysophosphatidic acid production,” Biochimica et Biophysica Acta, vol. 1781, no. 9, pp. 513–518, 2008. View at Publisher · View at Google Scholar
  7. W. H. Moolenaar and A. Perrakis, “Insights into autotaxin: how to produce and present a lipid mediator,” Nature Reviews Molecular Cell Biology, vol. 12, no. 10, pp. 674–679, 2011. View at Publisher · View at Google Scholar
  8. F. X. Yu, B. Zhao, N. Panupinthu et al., “Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling,” Cell, vol. 150, no. 4, pp. 780–791, 2012. View at Google Scholar
  9. E. Barbayianni, E. Kaffe, V. Aidinis, and G. Kokotos, “Autotaxin, a secreted lysophospholipase D, as a promising therapeutic target in chronic inflammation and cancer,” Progress in Lipid Research, vol. 58, pp. 76–96, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. Y. Miyabe, C. Miyabe, Y. Iwai et al., “Necessity of lysophosphatidic acid receptor 1 for development of arthritis,” Arthritis & Rheumatism, vol. 65, no. 8, pp. 2037–2047, 2013. View at Publisher · View at Google Scholar
  11. I. Nikitopoulou, N. Oikonomou, E. Karouzakis et al., “Autotaxin expression from synovial fibroblasts is essential for the pathogenesis of modeled arthritis,” The Journal of Experimental Medicine, vol. 209, no. 5, pp. 925–933, 2012. View at Google Scholar
  12. H. Nochi, H. Tomura, M. Tobo et al., “Stimulatory role of lysophosphatidic acid in cyclooxygenase-2 induction by synovial fluid of patients with rheumatoid arthritis in fibroblast-like synovial cells,” The Journal of Immunology, vol. 181, no. 7, pp. 5111–5119, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Cossa, L. Gatti, G. Cassinelli, C. Lanzi, N. Zaffaroni, and P. Perego, “Modulation of sensitivity to antitumor agents by targeting the MAPK survival pathway,” Current Pharmaceutical Design, vol. 19, no. 5, pp. 883–894, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Cargnello and P. P. Roux, “Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases,” Microbiol Mol Biol Rev, vol. 75, no. 1, pp. 50–83, 2011. View at Publisher · View at Google Scholar
  15. J. Zwerina, S. Hayer, K. Redlich et al., “Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction,” Arthritis Rheum, vol. 54, no. 2, pp. 463–472, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Ohori, “ERK inhibitors as a potential new therapy for rheumatoid arthritis,” Drug News & Perspectives, vol. 21, no. 5, pp. 245–250, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. Z. Han, D. L. Boyle, L. Chang et al., “c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis,” The Journal of Clinical Investigation, vol. 108, no. 1, pp. 73–81, 2001. View at Publisher · View at Google Scholar
  18. F. Salvo, A. Fourrier-Reglat, F. Bazin et al., “Cardiovascular and gastrointestinal safety of NSAIDs: a systematic review of meta-analyses of randomized clinical trials,” Clinical Pharmacology & Therapeutics, vol. 89, no. 6, pp. 855–866, 2011. View at Publisher · View at Google Scholar
  19. M. C. Huang, F. T. Pai, C. C. Lin et al., “Characteristics of traditional Chinese medicine use in patients with rheumatoid arthritis in Taiwan: A nationwide population-based study,” Journal of Ethnopharmacology, vol. 176, pp. 9–16, 2015. View at Google Scholar
  20. L. Shi, L. Xu, Y. Yang, H. Song, H. Pan, and L. Yin, “Suppressive effect of modified Simiaowan on experimental gouty arthritis: an in vivo and in vitro study,” Journal of Ethnopharmacology, vol. 150, no. 3, pp. 1038–1044, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. D. D. Brand, K. A. Latham, and E. F. Rosloniec, “Collagen-induced arthritis,” Nature Protocols, vol. 2, no. 5, pp. 1269–1275, 2007. View at Google Scholar
  22. N. Yeremenko, P. Harle, T. Cantaert et al., “The cartilage protein melanoma inhibitory activity contributes to inflammatory arthritis,” Rheumatology (Oxford), vol. 53, no. 3, pp. 438–447, 2014. View at Google Scholar
  23. A. Koyama, A. Tanaka, and H. To, “Daily oral administration of low-dose methotrexate has greater antirheumatic effects in collagen-induced arthritis rats,” Journal of Pharmacy and Pharmacology, vol. 69, no. 9, pp. 1145–1154, 2017. View at Publisher · View at Google Scholar · View at Scopus
  24. E. Zhao, L. Wang, J. Dai et al., “Regulatory T cells in the bone marrow microenvironment in patients with prostate cancer,” OncoImmunology, vol. 1, no. 2, pp. 152–161, 2012. View at Publisher · View at Google Scholar
  25. F. L. Yuan, F. H. Chen, W. G. Lu et al., “Inhibition of acid-sensing ion channels in articular chondrocytes by amiloride attenuates articular cartilage destruction in rats with adjuvant arthritis,” Inflammation Research, vol. 59, no. 11, pp. 939–947, 2010. View at Google Scholar
  26. A. D. Lower-Nedza, C. Kuess, H. Y. Zhao, B. L. Bian, and A. H. Brantner, “In vitro anti-inflammatory and antioxidant potential of Si-Miao-San, its modifications and pure compounds,” Natural Product Communications (NPC), vol. 8, no. 8, pp. 1137–1141, 2013. View at Google Scholar · View at Scopus
  27. C. H. Ma, L. L. Kang, H. M. Ren, D. M. Zhang, and L. D. Kong, “Simiao pill ameliorates renal glomerular injury via increasing Sirt1 expression and suppressing NF-κB/NLRP3 inflammasome activation in high fructose-fed rats,” Journal of Ethnopharmacology, vol. 172, pp. 108–117, 2015. View at Publisher · View at Google Scholar
  28. I. B. McInnes and G. Schett, “Cytokines in the pathogenesis of rheumatoid arthritis,” Nature Reviews Immunology, vol. 7, no. 6, pp. 429–442, 2007. View at Google Scholar
  29. J. R. Kalden and H. Schulze-Koops, “Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment,” Nature Reviews Rheumatology, vol. 13, no. 12, pp. 707–718, 2017. View at Publisher · View at Google Scholar
  30. C. A. Dinarello, “Blocking IL-1 in systemic inflammation,” The Journal of Experimental Medicine, vol. 201, no. 9, pp. 1355–1359, 2005. View at Google Scholar
  31. J.-Y. Choe, S.-J. Lee, S.-H. Park, and S.-K. Kim, “Tacrolimus (FK506) inhibits interleukin-1β-induced angiopoietin-1, Tie-2 receptor, and vascular endothelial growth factor through down-regulation of JNK and p38 pathway in human rheumatoid fibroblast-like synoviocytes,” Joint Bone Spine, vol. 79, no. 2, pp. 137–143, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. T. Thalhamer, M. A. McGrath, and M. M. Harnett, “MAPKs and their relevance to arthritis and inflammation,” Rheumatology, vol. 47, no. 4, pp. 409–414, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. V. Paunovic and M. M. Harnett, “Mitogen-activated protein kinases as therapeutic targets for rheumatoid arthritis,” Drugs, vol. 73, no. 2, pp. 101–115, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. I. Ninou, C. Magkrioti, and V. Aidinis, “Autotaxin in pathophysiology and pulmonary fibrosis,” Frontiers in Medicine, vol. 5, p. 180, 2018. View at Google Scholar · View at Scopus
  35. L. A. van Meeteren, P. Ruurs, C. Stortelers et al., “Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development,” Molecular and Cellular Biology, vol. 26, no. 13, pp. 5015–5022, 2006. View at Google Scholar
  36. S. Fotopoulou, N. Oikonomou, E. Grigorieva et al., “ATX expression and LPA signalling are vital for the development of the nervous system,” Developmental Biology, vol. 339, no. 2, pp. 451–464, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Gierse, A. Thorarensen, K. Beltey et al., “A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation,” Journal of Pharmacology and Experimental Therapeutics, vol. 334, no. 1, pp. 310–317, 2010. View at Publisher · View at Google Scholar
  38. L. A. van Meeteren and W. H. Moolenaar, “Regulation and biological activities of the autotaxin-LPA axis,” Progress in Lipid Research, vol. 46, no. 2, pp. 145–160, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. Y. Miyabe, C. Miyabe, Y. Iwai et al., “Activation of fibroblast-like synoviocytes derived from rheumatoid arthritis via lysophosphatidic acid-lysophosphatidic acid receptor 1 cascade,” Arthritis Research & Therapy, vol. 16, no. 1, p. 461, 2014. View at Google Scholar · View at Scopus
  40. C. Zhao, M. J. Fernandes, G. D. Prestwich et al., “Regulation of lysophosphatidic acid receptor expression and function in human synoviocytes: implications for rheumatoid arthritis?” Molecular Pharmacology, vol. 73, no. 2, pp. 587–600, 2008. View at Google Scholar
  41. M. G. K. Benesch, Y. M. Ko, T. P. W. McMullen, and D. N. Brindley, “Autotaxin in the crosshairs: Taking aim at cancer and other inflammatory conditions,” FEBS Letters, vol. 588, no. 16, pp. 2712–2727, 2014. View at Publisher · View at Google Scholar · View at Scopus
  42. I. Sevastou, E. Kaffe, M.-A. Mouratis, and V. Aidinis, “Lysoglycerophospholipids in chronic inflammatory disorders: the PLA2/LPC and ATX/LPA axes,” Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, vol. 1831, no. 1, pp. 42–60, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Boucharaba, C. Serre, S. Grès et al., “Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer,” The Journal of Clinical Investigation, vol. 114, no. 12, pp. 1714–1725, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. M. T. Rizzo, E. Nguyen, M. Aldo-Benson, and G. Lambeau, “Secreted phospholipase A2 induces vascular endothelial cell migration,” Blood, vol. 96, no. 12, pp. 3809–3815, 2000. View at Google Scholar · View at Scopus
  45. J. S. Bomalaski, M. A. Clark, S. D. Douglas, and R. B. Zurier, “Enhanced phospholipase A2 and C activities of peripheral blood polymorphonuclear leukocytes from patients with rheumatoid arthritis,” Journal of Leukocyte Biology, vol. 38, no. 5, pp. 649–654, 1985. View at Publisher · View at Google Scholar · View at Scopus
  46. M.-M. Thwin, E. Douni, P. Arjunan, G. Kollias, P. V. Kumar, and P. Gopalakrishnakone, “Suppressive effect of secretory phospholipase A2 inhibitory peptide on interleukin-1β-induced matrix metalloproteinase production in rheumatoid synovial fibroblasts, and its antiarthritic activity in hTNFtg mice,” Arthritis Research & Therapy, vol. 11, no. 5, p. R138, 2009. View at Google Scholar · View at Scopus
  47. G. Kokotos, A. J. Feuerherm, E. Barbayianni et al., “Inhibition of group IVA cytosolic phospholipase A2by thiazolyl ketones in vitro, ex vivo, and in vivo,” Journal of Medicinal Chemistry, vol. 57, no. 18, pp. 7523–7535, 2014. View at Publisher · View at Google Scholar · View at Scopus